What is Cagrilintide? Cagrilintide (also known as AM833/NNC0174-0833) is a long-acting synthetic amylin analogue and dual amylin/calcitonin receptor agonist (DACRA). It mimics the hormone amylin, which is co-secreted with insulin and helps regulate appetite and slow gastric emptying — mechanisms that support weight control and metabolic health. It is being developed for weight management and type 2 diabetes, and has been studied alone and in combination with GLP-1 receptor agonists (e.g., semaglutide) under names like CagriSema. Benefits: 1. Appetite Suppression and Satiety Cagrilintide activates amylin pathways in the brain helping you feel fuller, reduce hunger signals, and eat less overall. 2. Weight Loss In trials: ● As monotherapy, it produces significant weight reduction. ● In combination with semaglutide (CagriSema), mean weight loss up to ~22.7% has been reported, a very high efficacy among obesity meds. 3. Metabolic Improvements Studies show better glycemic control (lower HbA1c) and improvements in metabolic markers like triglycerides and insulin sensitivity. 4. Convenient Dosing Once-weekly subcutaneous injections make it easy to integrate into regimens similar to GLP-1 therapies. Dosing: Because cagrilintide is not FDA-approved yet, dosing schedules vary across clinical studies. The common theme is gradual weekly titration to help reduce side effects. If using a GLP, dose Cagrilintide 2-3 days after your GLP injection. A typical dose escalation in trials looked like: ● Weeks 1–4: ~0.25–0.3 mg/week ● Weeks 5–8: ~0.5–0.6 mg/week ● Weeks 9–12: ~1.0–1.2 mg/week ● Weeks 13–16: ~1.7–2.4 mg/week ● Maintenance: ~2.4 mg/week (some trials explored up to 4.5 mg) Maximum doses in research did not exceed ~4.5 mg/week. Combination with Semaglutide (CagriSema) Clinical trial protocols often matched cagrilintide titration with semaglutide escalation: ● Cagrilintide → 0.6 → 1.2 → 1.8 → 2.4 mg weekly ● Semaglutide → 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly